S. Huan

1.2k total citations
36 papers, 1.0k citations indexed

About

S. Huan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, S. Huan has authored 36 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 8 papers in Cancer Research. Recurrent topics in S. Huan's work include Cancer Treatment and Pharmacology (11 papers), Neutropenia and Cancer Infections (7 papers) and Bladder and Urothelial Cancer Treatments (5 papers). S. Huan is often cited by papers focused on Cancer Treatment and Pharmacology (11 papers), Neutropenia and Cancer Infections (7 papers) and Bladder and Urothelial Cancer Treatments (5 papers). S. Huan collaborates with scholars based in Canada, United States and Belgium. S. Huan's co-authors include Malcolm J. Moore, Ian F. Tannock, Nevin Murray, D. Scott Ernst, Jonathan C. Yau, Roanne Segal, Lesley Seymour, Katherine Bennett, Eric Winquist and Wendy Walsh and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

S. Huan

36 papers receiving 982 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Huan Canada 16 439 383 334 163 160 36 1.0k
C. Sternberg Italy 16 397 0.9× 225 0.6× 606 1.8× 228 1.4× 210 1.3× 67 1.1k
Nancy B. Davis United States 16 472 1.1× 220 0.6× 372 1.1× 175 1.1× 297 1.9× 61 989
Enzo Maria Ruggeri Italy 22 681 1.6× 354 0.9× 535 1.6× 279 1.7× 274 1.7× 103 1.4k
Brigitte Duclos France 20 508 1.2× 531 1.4× 769 2.3× 280 1.7× 627 3.9× 52 1.6k
Loı̈c Mourey France 16 565 1.3× 271 0.7× 882 2.6× 277 1.7× 206 1.3× 107 1.5k
Luis Paz‐Ares Spain 13 784 1.8× 525 1.4× 675 2.0× 239 1.5× 357 2.2× 27 1.6k
M. Neil Reaume Canada 18 461 1.1× 234 0.6× 642 1.9× 218 1.3× 302 1.9× 66 1.1k
Josep R. Germà Spain 17 524 1.2× 331 0.9× 330 1.0× 141 0.9× 360 2.3× 29 1.1k
Marisa T. Carriaga United States 6 357 0.8× 322 0.8× 250 0.7× 190 1.2× 106 0.7× 6 771
Tadao Takano Japan 20 232 0.5× 251 0.7× 117 0.4× 112 0.7× 238 1.5× 54 1.1k

Countries citing papers authored by S. Huan

Since Specialization
Citations

This map shows the geographic impact of S. Huan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Huan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Huan more than expected).

Fields of papers citing papers by S. Huan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Huan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Huan. The network helps show where S. Huan may publish in the future.

Co-authorship network of co-authors of S. Huan

This figure shows the co-authorship network connecting the top 25 collaborators of S. Huan. A scholar is included among the top collaborators of S. Huan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Huan. S. Huan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hirte, Hal W., David J. Stewart, Rakesh Goel, et al.. (2005). An NCIC-CTG phase I dose escalation pharmacokinetic study of the matrix metalloproteinase inhibitor BAY 12-9566 in combination with doxorubicin. Investigational New Drugs. 23(5). 437–443. 4 indexed citations
2.
Gelmon, Karen A., Doug Stewart, Stephen Chia, et al.. (2004). A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131. Annals of Oncology. 15(7). 1115–1122. 18 indexed citations
3.
Miller, Wilson H., Leonard Reyno, Gordon Loewen, et al.. (2000). A phase I-II study of 9-cis retinoic acid and interferon-α2b in patients with advanced renal-cell carcinoma: An NCIC Clinical Trials Group study. Annals of Oncology. 11(11). 1387–1389. 12 indexed citations
4.
Yau, Jonathan C., John Hanson, Shailendra Verma, et al.. (2000). A Phase III Study of High-Dose Intensification Without Hematopoietic Progenitor Cells Support for Patients With High-Risk Primary Breast Carcinoma. American Journal of Clinical Oncology. 23(3). 292–296. 4 indexed citations
5.
Hao, Desirée, et al.. (2000). A Pilot Study of Low Dose Hydroxyurea as a Novel Resistance Modulator in Metastatic Renal Cell Cancer. Journal of Chemotherapy. 12(4). 360–366. 2 indexed citations
6.
Crook, Juanita, Ewa Szumacher, Shawn Malone, S. Huan, & Roanne Segal. (1999). Intermittent androgen suppression in the management of prostate cancer. Urology. 53(3). 530–534. 97 indexed citations
7.
Huan, S., et al.. (1999). Combination of Epirubicin and Cisplatin in Hormone-Refractory Metastatic Prostate Cancer. American Journal of Clinical Oncology. 22(5). 471–471. 24 indexed citations
8.
Moore, Malcolm J., Ian F. Tannock, D. Scott Ernst, S. Huan, & Nevin Murray. (1997). Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.. Journal of Clinical Oncology. 15(12). 3441–3445. 222 indexed citations
9.
Cripps, M. Christine, Rakesh Goel, Simone Dahrouge, et al.. (1997). Pilot study of multiple chemotherapy resistance modulators plus epirubicin in the treatment of resistant malignancies. Cancer Chemotherapy and Pharmacology. 41(1). 1–8. 4 indexed citations
10.
Stewart, David J., et al.. (1997). Multiple resistance modulators combined with carboplatin for resistant malignancies: A pilot study. Investigational New Drugs. 15(4). 267–277. 5 indexed citations
11.
Huan, S., Ronald G. Gerridzen, Jonathan C. Yau, & David J. Stewart. (1997). Antiandrogen withdrawal syndrome with nilutamide. Urology. 49(4). 632–634. 40 indexed citations
12.
Huan, S., et al.. (1995). A phase II study of 5-fluorouracil and high dose folinic acid in cisplatin-refractory metastatic bladder cancer. Annals of Oncology. 6(8). 836–837. 12 indexed citations
13.
Dunphy, Frank, Gary Spitzer, Jane Fornoff, et al.. (1994). Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. Cancer. 73(8). 2157–2167. 79 indexed citations
14.
Huan, S., et al.. (1994). 5-Fluorouracil and high dose folinic acid in hormone-refractory metastatic prostate cancer: A phase II study. Annals of Oncology. 5(7). 644–645. 13 indexed citations
15.
Yau, Jonathan C., Meletios Α. Dimopoulos, S. Huan, et al.. (1991). Prophylaxis of cytomegalovirus infection with ganciclovir in allogeneic marrow transplantation. European Journal Of Haematology. 47(5). 371–376. 20 indexed citations
16.
Huan, S., Sewa S. Legha, Martin N. Raber, & Irwin H. Krakoff. (1991). Phase I studies of trimetrexate using single and weekly dose schedules. Investigational New Drugs. 9(2). 199–206. 8 indexed citations
17.
Yau, Jonathan C., S. Huan, Meletios Α. Dimopoulos, et al.. (1991). An effective acute graft‐vs.‐host disease prophylaxis with minidose methotrexate, cyclosporine, and single‐dose methylprednisolone. American Journal of Hematology. 38(4). 288–292. 7 indexed citations
18.
Huan, S., Jonathan C. Yau, Frank Dunphy, et al.. (1991). Impact of autologous bone marrow infusion on hematopoietic recovery after high-dose cyclophosphamide, etoposide, and cisplatin.. Journal of Clinical Oncology. 9(9). 1609–1617. 16 indexed citations
19.
Wallerstein, Ralph O., Gary Spitzer, Frank Dunphy, et al.. (1990). A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer.. Journal of Clinical Oncology. 8(11). 1782–1788. 43 indexed citations
20.
Spitzer, Gary, Albert Deisseroth, Gerard J. Ventura, et al.. (1990). Use of recombinant human hematopoietic growth factors and autologous bone marrow transplantation to attenuate the neutropenic trough of high-dose therapy. Stem Cells. 8(S1). 249–261. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C. Sternberg Breakdown of academic impact, for papers by Nancy B. Davis Breakdown of academic impact, for papers by Enzo Maria Ruggeri Breakdown of academic impact, for papers by Brigitte Duclos Breakdown of academic impact, for papers by Loı̈c Mourey Breakdown of academic impact, for papers by Luis Paz‐Ares Breakdown of academic impact, for papers by M. Neil Reaume Breakdown of academic impact, for papers by Josep R. Germà Breakdown of academic impact, for papers by Marisa T. Carriaga Breakdown of academic impact, for papers by Tadao Takano
Rankless by CCL
2026